Molecular Partners AG - American Depositary Shares (MOLN)
MOLN moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How MOLN actually reacts to news — the realized, point-in-time move the market made, measured across 179 labeled events over the last three years with zero look-ahead.
MOLN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 29% | 109 |
| 30-min | 0.00% | 37% | 124 |
| 60-min | 0.00% | 41% | 142 |
| to close | 0.00% | 46% | 173 |
| Middle 50% of MOLN reactions | -1.74% to +0.70% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 179 |
Half of all Molecular Partners AG - American Depositary Shares news events land between -1.74% and +0.70% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MOLN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MOLN's baseline. Nothing else.
Recent MOLN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K MOLECULAR PARTNERS AG For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -5.05% | +0.69% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jul 16 | SEC filing · Form 6-K | SEC EDGAR | — | +1.01% | |
| Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma | Press release | GlobeNewswire | — | +2.50% | |
| Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference | Press release | GlobeNewswire | — | -2.49% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jul 06 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.25% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jul 02 | SEC filing · Form 6-K | SEC EDGAR | +2.24% | -0.75% | |
| Form S-8 MOLECULAR PARTNERS AG | SEC filing · Form S-8 | SEC EDGAR | — | +3.15% | |
| Form 6-K MOLECULAR PARTNERS AG For: May 30 | SEC filing · Form 6-K | SEC EDGAR | — | -3.66% | |
| Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors | Press release | GlobeNewswire | — | — | |
| Form 6-K MOLECULAR PARTNERS AG For: Mar 12 | SEC filing · Form 6-K | SEC EDGAR | — | -8.26% | |
| Form 20-F MOLECULAR PARTNERS AG For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -2.91% | -8.86% | |
| Form 6-K MOLECULAR PARTNERS AG For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | -2.91% | -8.86% | |
| Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results | Press release | GlobeNewswire | +1.32% | -1.01% | |
| Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics | Press release | GlobeNewswire | +1.32% | -1.01% | |
| Form 6-K MOLECULAR PARTNERS AG For: Feb 02 | SEC filing · Form 6-K | SEC EDGAR | -0.25% | -0.65% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jan 11 | SEC filing · Form 6-K | SEC EDGAR | — | +0.00% | |
| Form 6-K MOLECULAR PARTNERS AG For: Dec 07 | SEC filing · Form 6-K | SEC EDGAR | -5.49% | -3.80% | |
| Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting | Press release | GlobeNewswire | -5.49% | -3.80% | |
| Form 6-K MOLECULAR PARTNERS AG For: Nov 12 | SEC filing · Form 6-K | SEC EDGAR | — | -2.82% | |
| Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action | Press release | GlobeNewswire | — | -2.82% | |
| Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 | Press release | GlobeNewswire | +0.76% | +2.64% | |
| Form 6-K MOLECULAR PARTNERS AG For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | — | -0.45% | |
| Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 | Press release | GlobeNewswire | — | -0.45% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.08% | -0.26% | |
| Form S-8 MOLECULAR PARTNERS AG | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.19% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | -0.54% | +3.78% | |
| Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway | Press release | GlobeNewswire | -2.12% | -6.88% | |
| Form 6-K MOLECULAR PARTNERS AG For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | — | +0.00% | |
| Form 6-K MOLECULAR PARTNERS AG For: Apr 29 | SEC filing · Form 6-K | SEC EDGAR | -1.54% | +0.52% | |
| Form EFFECT MOLECULAR PARTNERS AG | SEC filing · Form EFFECT | SEC EDGAR | +1.47% | +2.67% | |
| Form F-3 MOLECULAR PARTNERS AG | SEC filing · Form F-3 | SEC EDGAR | — | -0.26% | |
| Form 20-F MOLECULAR PARTNERS AG For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | — | +11.33% | |
| Form 6-K MOLECULAR PARTNERS AG For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | — | +11.33% | |
| Form 6-K MOLECULAR PARTNERS AG For: Mar 06 | SEC filing · Form 6-K | SEC EDGAR | — | +11.33% | |
| Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call | Press release | GlobeNewswire | +0.00% | +4.90% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jan 12 | SEC filing · Form 6-K | SEC EDGAR | — | -1.47% | |
| Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 | Press release | GlobeNewswire | — | -1.75% | |
| Form 6-K MOLECULAR PARTNERS AG For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | — | -0.33% | |
| Form 6-K MOLECULAR PARTNERS AG For: Oct 28 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -6.49% | |
| Molecular Partners Announces Pricing of $20 Million Underwritten Offering | Press release | GlobeNewswire | +0.15% | -0.61% | |
| Form 6-K MOLECULAR PARTNERS AG For: Oct 22 | SEC filing · Form 6-K | SEC EDGAR | +0.89% | -10.00% | |
| Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 | Press release | GlobeNewswire | +0.89% | -10.00% | |
| Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics | Press release | GlobeNewswire | +0.89% | -10.00% | |
| Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting | Press release | GlobeNewswire | +0.00% | +9.13% | |
| Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 | Press release | GlobeNewswire | — | +4.54% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +8.98% | |
| Form S-8 MOLECULAR PARTNERS AG | SEC filing · Form S-8 | SEC EDGAR | -2.75% | -2.87% | |
| Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit | Press release | GlobeNewswire | -1.30% | -0.14% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jun 14 | SEC filing · Form 6-K | SEC EDGAR | +0.15% | +2.42% | |
| Form 6-K MOLECULAR PARTNERS AG For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | — | +3.10% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MOLN section they belong to.
Where else MOLN is measured.
MOLN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Molecular Partners AG - American Depositary Shares's median reaction calculated?
Every labeled MOLN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 179 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of MOLN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MOLN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.